Compounds > xanomeline
Page last updated: 2024-08-24

xanomeline and Disease Models, Animal

xanomeline has been researched along with Disease Models, Animal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dong, S; Duan, Y; Jia, K; Li, Z; Wang, D; Zhou, Z1
Cao, X; Hu, JF; Hu, Y; Lei, X; Mei, B; Niu, Y; Su, J; Wang, D; Xiong, J; Yang, L1
Coupal, M; Gilbert, AK; Laird, JMA; Markoglou, N; Martino, G; McIntosh, FS; Perkins, MN; Puma, C; Yu, XH1
Crawley, JN; McDonald, MP; Wenk, GL; Willard, LB1
Bymaster, FP; Fink-Jensen, A; Hart, JC; Jeppesen, L; Peters, SC; Rasmussen, K; Sauerberg, P; Shannon, HE; Sheardown, MJ; Swedberg, MD1

Other Studies

5 other study(ies) available for xanomeline and Disease Models, Animal

ArticleYear
Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
    Molecular medicine reports, 2017, Volume: 16, Issue:5

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cerebral Cortex; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression; Hippocampus; Male; Maze Learning; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Pyridines; Thiadiazoles

2017
Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
    Biochemical and biophysical research communications, 2011, Jul-01, Volume: 410, Issue:2

    Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Glial Fibrillary Acidic Protein; Mice; Mice, Knockout; Muscarinic Agonists; Nerve Tissue Proteins; Phosphorylation; Presenilin-1; Presenilin-2; Pyridines; tau Proteins; Thiadiazoles

2011
The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
    Pain, 2011, Volume: 152, Issue:12

    Topics: Analgesics; Animals; Central Nervous System; CHO Cells; Chronic Pain; Cricetinae; Cricetulus; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Muscarinic Agonists; Neuralgia; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Thiadiazoles

2011
Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998, Jul-01, Volume: 18, Issue:13

    Topics: Acetylcholine; Alzheimer Disease; Animals; Antibodies, Monoclonal; Behavior, Animal; Choice Behavior; Cholinergic Agents; Cholinergic Fibers; Cognition; Disease Models, Animal; Dose-Response Relationship, Drug; Galanin; Immunotoxins; Male; Memory; Muscarinic Agonists; N-Glycosyl Hydrolases; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptors, Muscarinic; Ribosome Inactivating Proteins, Type 1; Saporins; Thiadiazoles

1998
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
    Schizophrenia research, 2000, May-05, Volume: 42, Issue:3

    Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Brain; Cholinergic Agonists; Conditioning, Psychological; Disease Models, Animal; Dopamine; Electrophysiology; Male; Mice; Mice, Inbred Strains; Muscarinic Agonists; Neurons; Psychotic Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Schizophrenia; Thiadiazoles

2000